There are 1105 resources available
53P - Real-world treatment patterns for HER2+ and HR+/HER2- advanced breast cancer in county areas of China
Presenter: Yinghua Ji
Session: Poster Display session
Resources:
Abstract
55P - A retrospective study to investigate the prevalence and describe the treatment outcomes of HER2-low unresectable and/or metastatic breast cancer in Taiwan: The RetroBC-HER2L-TW study
Presenter: Chih-Yi Hsu
Session: Poster Display session
Resources:
Abstract
56P - Palbociclib versus ribociclib in first-line therapy of patients with metastatic breast cancer: Direct comparison in real-world practice
Presenter: Elena Tsareva
Session: Poster Display session
Resources:
Abstract
62P - Patient satisfaction and preference for atezolizumab subcutaneous (atezo SC) by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002
Presenter: Busyamas Chewaskulyong
Session: Poster Display session
Resources:
Abstract
63P - A randomised, double-blind, phase I study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of HLX15 and daratumumab in healthy male participants
Presenter: Yu-wen Su
Session: Poster Display session
Resources:
Abstract
64P - FGF19 promotes hepatocellular carcinoma evasion of immune response by stabilizing PD-L1
Presenter: Jing Zhou
Session: Poster Display session
Resources:
Abstract
65P - The role of desmocollin-3 glycoprotein in EMT-driven melanomagenesis: Implications for progression and patient outcome
Presenter: Saber Imani
Session: Poster Display session
Resources:
Abstract
66P - Comprehensive analysis of hippo pathway dysregulation in uveal melanoma: Towards prognostic biomarkers and therapeutic targets
Presenter: Nikhil Kumar
Session: Poster Display session
Resources:
Abstract
67P - Bioplatin, a novel oral platinum-based compound: Potential for cancer prevention and treatment in SCID mice using xenograft models of prostate cancer
Presenter: Yogesh Bendale
Session: Poster Display session
Resources:
Abstract
68P - Patient-reported outcomes (PROs) in Chinese patients with mantle cell lymphoma (MCL) after covalent Bruton’s tyrosine kinase inhibitor (cBTKi) treatment: Post-hoc analysis from a phase II study
Presenter: Yanyan Liu
Session: Poster Display session
Resources:
Abstract